Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

GH Research PLC

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DUBLIN, JUNE 04, 2026 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS) TODAY ANNOUNCED THE PUBLICATION OF THE FULL RESULTS FROM ITS PHASE 2A TRIAL IN POSTPARTUM DEPRESSION (PPD) AND THE ACCEPTANCE OF TWO ORAL PRESENTATIONS AT THE 37TH WORLD CONGRESS OF NEUROPSYCHOPHARMACOLOGY (CINP 2026). THE PEER-REVIEWED ARTICLE, TITLED INHALED MEBUFOTENIN (GH001) FOR ADULT PATIENTS WITH POSTPARTUM DEPRESSION: A PHASE 2A OPEN-LABEL CLINICAL TRIAL, HAS BEEN PUBLISHED IN THE JOURNAL OF CLINICAL PSYCHIATRY (DOI: 10.4088/JCP.25M16284).

GH RESEARCH ANNOUNCES PUBLICATION OF PHASE 2A POSTPARTUM DEPRESSION RESULTS

PHASE 2B RESULTS IN TRD PUBLISHED INJAMA PSYCHIATRY GH001-HV-106 STUDY ENROLMENT COMPLETED; DOSES SELECTED FOR THE GLOBAL PHASE 3 PIVOTAL PROGRAM OF GH001 IN TRD GH001-HV-109 US IND-OPENING STUDY ENROLMENT COMPLETED CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $267.3 MILLION AS OF MARCH 31, 2026 NET CASH PROCEEDS OF AN ADDITIONAL $111.2 MILLION FROM UNDERWRITTEN OFFERING RECEIVED IN APRIL 2026 DUBLIN, MAY 14, 2026 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO TRANSFORMING THE LIVES OF PATIENTS BY DEVELOPING A PRACTICE-CHANGING TREATMENT IN DEPRESSION, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026, AND PROVIDED A BUSINESS UPDATE. BUSINESS UPDATES SCIENTIFIC PRESENTATIONS AND PUBLICATIONS IN MARCH 2026, THE RESULTS OF OUR PHASE 2B TRIAL IN TRD (GH001-TRD-201) WERE PUBLISHED IN JAMA PSYCHIATRY.

GH RESEARCH REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

DUBLIN, APRIL 29, 2026 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO TRANSFORMING THE LIVES OF PATIENTS BY DEVELOPING A PRACTICE-CHANGING TREATMENT IN DEPRESSION, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN OFFERING IN THE UNITED STATES OF 6,527,779 OF ITS ORDINARY SHARES AT AN OFFERING PRICE OF $18.00 PER SHARE FOR TOTAL GROSS PROCEEDS OF APPROXIMATELY $117.5 MILLION, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES. ALL OF THE ORDINARY SHARES ARE BEING OFFERED BY GH RESEARCH PLC.

GH RESEARCH ANNOUNCES PRICING OF $117.5 MILLION UNDERWRITTEN OFFERING

DUBLIN, APRIL 20, 2026 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO TRANSFORMING THE LIVES OF PATIENTS BY DEVELOPING A PRACTICE-CHANGING TREATMENT IN DEPRESSION, TODAY ISSUED A STATEMENT WELCOMING THE WHITE HOUSE EXECUTIVE ORDER, SIGNED ON APRIL 18, 2026, TO ACCELERATE MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS, INCLUDING INNOVATIVE PSYCHEDELIC MEDICAL TREATMENTS (THE EXECUTIVE ORDER). THE EXECUTIVE ORDER DIRECTS COORDINATED FEDERAL ACTION TO ACCELERATE THE DEVELOPMENT OF, AND EXPAND PATIENT ACCESS TO, INNOVATIVE THERAPIES FOR SERIOUS MENTAL ILLNESS.

GH RESEARCH WELCOMES WHITE HOUSE EXECUTIVE ORDER TO ACCELERATE MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS

DUBLIN, MARCH 25, 2026 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO TRANSFORMING THE LIVES OF PATIENTS BY DEVELOPING A PRACTICE-CHANGING TREATMENT IN DEPRESSION, TODAY ANNOUNCED TWO PEER-REVIEWED PUBLICATIONS FROM ITS PHASE 2B CLINICAL PROGRAM OF GH001 IN TREATMENT-RESISTANT DEPRESSION (TRD): THE PRIMARY TRIAL RESULTS IN JAMA PSYCHIATRY , AND A NEW ANALYSIS DEMONSTRATING THAT EFFICACY IS INDEPENDENT OF THE NUMBER OF PRIOR LIFETIME TREATMENT FAILURES IN A FORTHCOMING ISSUE OF PSYCHOPHARMACOLOGY BULLETIN.

GH RESEARCH ANNOUNCES PUBLICATION OF PHASE 2B RESULTS FOR MEBUFOTENIN (GH001) IN JAMA PSYCHIATRY AND REPORTS NEW FINDING OF SEVERITY-INDEPENDENT EFFICACY IN TRD

COMPLETED PHASE 2B TRIAL OF GH001 IN TRD AND PRESENTED THE FULL DATASET AT THE 2025 ASCP AND ECNP CONGRESSES GH001 CLEARED BY FDA FOR U.S. CLINICAL INVESTIGATION, ENABLING U.S. SUBJECT ENROLLMENT CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $280.7 MILLION AS OF DECEMBER 31, 2025 DUBLIN, IRELAND, MARCH 05, 2026 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO TRANSFORMING THE LIVES OF PATIENTS BY DEVELOPING A PRACTICE-CHANGING TREATMENT IN DEPRESSION, TODAY REPORTED FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025, AND PROVIDED A BUSINESS UPDATE. BUSINESS UPDATE IN 2025, THE COMPANY COMPLETED ITS PHASE 2B TRIAL OF GH001 IN TREATMENT-RESISTANT DEPRESSION (TRD) AND PRESENTED THE FULL DATASET AT THE 2025 AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY (ASCP) ANNUAL MEETING IN ARIZONA, AND THE 2025 EUROPEAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY (ECNP) CONGRESS IN AMSTERDAM.

GH RESEARCH REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

GH001 CLEARED BY FDA FOR U.S. CLINICAL INVESTIGATION, ENABLING U.S. SUBJECT ENROLLMENT COMPANY TO SEEK FDA ALIGNMENT ON GLOBAL PHASE 3 PROGRAM REPLICATING PHASE 2B DESIGN PHASE 3 INITIATION TARGETED FOR 2026 DUBLIN, JAN. 05, 2026 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO TRANSFORMING THE LIVES OF PATIENTS BY DEVELOPING A PRACTICE-CHANGING TREATMENT IN DEPRESSION, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS LIFTED THE CLINICAL HOLD ON ITS INVESTIGATIONAL NEW DRUG APPLICATION (IND) FOR GH001. THIS CLEARANCE ENABLES U.S. SUBJECT ENROLLMENT AND PROGRESSES THE COMPANY TOWARD ALIGNMENT OF ITS DEVELOPMENT ACROSS MAJOR JURISDICTIONS.

GH RESEARCH ANNOUNCES FDA LIFTS CLINICAL HOLD ON GH001, CLEARING PATH FOR GLOBAL PHASE 3 INITIATION IN 2026

DUBLIN, JAN. 02, 2026 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO TRANSFORMING THE LIVES OF PATIENTS BY DEVELOPING A PRACTICE-CHANGING TREATMENT IN DEPRESSION, TODAY REPORTED THAT IT WILL PROVIDE AN UPDATE ON THE STATUS OF ITS INVESTIGATIONAL NEW DRUG APPLICATION (IND) FOR GH001 WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) AND ITS GLOBAL PIVOTAL PHASE 3 PROGRAM IN TREATMENT-RESISTANT DEPRESSION (TRD) ON MONDAY, JANUARY 5, 2026, AT 7.00 A.M. EST. ABOUT GH RESEARCH PLC GH RESEARCH PLC IS A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO TRANSFORMING THE LIVES OF PATIENTS BY DEVELOPING A PRACTICE-CHANGING TREATMENT IN DEPRESSION.

GH RESEARCH TO ANNOUNCE IND STATUS FOR GH001

ENGAGEMENT WITH FDA ON GH001 IND COMPLETE RESPONSE ONGOING FULL DATASET FROM THE PHASE 2B CLINICAL TRIAL OF GH001 IN TRD REPORTED IN JULY 2025 LONG-TERM CLINICAL DATA ON SAFETY AND EFFICACY FROM OPEN-LABEL EXTENSION PRESENTED AT ECNP IN OCTOBER 2025 CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $293.9 MILLION AS OF SEPTEMBER 30, 2025 DUBLIN, NOV. 06, 2025 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO TRANSFORMING THE LIVES OF PATIENTS BY DEVELOPING A PRACTICE-CHANGING TREATMENT IN DEPRESSION, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED UPDATES ON ITS BUSINESS. BUSINESS UPDATES GH001 UPDATE IN JULY 2025, WE ANNOUNCED THAT WE RECEIVED A COMMUNICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) RELATING TO OUR COMPLETE RESPONSE TO THE CLINICAL HOLD OF OUR INVESTIGATIONAL NEW DRUG APPLICATION (IND) FOR GH001, WITH ONLY ONE HOLD TOPIC REMAINING.

GH RESEARCH REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

DUBLIN, OCT. 09, 2025 (GLOBE NEWSWIRE) -- GH RESEARCH PLC (NASDAQ: GHRS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEDICATED TO TRANSFORMING THE LIVES OF PATIENTS BY DEVELOPING A PRACTICE-CHANGING TREATMENT IN DEPRESSION, TODAY ANNOUNCED THE ACCEPTANCE OF A NOVEL THERAPIES SYMPOSIUM PRESENTATION AT THE 38TH ANNUAL EUROPEAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY CONGRESS (ECNP) IN AMSTERDAM, THE NETHERLANDS FROM OCTOBER 11  14, WHERE PROFESSOR WIESAW J. CUBAA, MD, PHD, DEPARTMENT OF PSYCHIATRY, FACULTY OF MEDICINE, MEDICAL UNIVERSITY OF GDASK, WILL PRESENT LONG-TERM CLINICAL DATA ON THE SAFETY AND EFFICACY FROM THE OPEN LABEL EXTENSION (OLE) OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B CLINICAL TRIAL WITH GH001 IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION (TRD) (GH001-TRD-201).

GH Research PLC

GHRS

Price

Financial Reports

No items found.

Press Releases

GH Research PLC

GHRS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

GHRS